Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Kurt S. Bantilan, Neil E. Kay, Sameer A. Parikh, Kari G. Rabe, Timothy G. Call, Jose F. Leis, Wei Ding, Susan L. Slager, Jacob D. Soumerai, Lindsey E. Roeker, Anthony Mato & Andrew D. Zelenetz. (2023) Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leukemia & Lymphoma 64:2, pages 300-311.
Read now
Read now
Constantine S. Tam & Stephan Stilgenbauer. (2015) How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?. Leukemia & Lymphoma 56:3, pages 587-593.
Read now
Read now
Davide Rossi & Gianluca Gaidano. (2012) Molecular genetics of high-risk chronic lymphocytic leukemia. Expert Review of Hematology 5:6, pages 593-602.
Read now
Read now
Giles Best, Philip Thompson & Constantine S. Tam. (2012) Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia. Leukemia & Lymphoma 53:11, pages 2105-2115.
Read now
Read now
Carmen Diana Schweighofer & Clemens-Martin Wendtner. (2010) First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. OncoTargets and Therapy 3, pages 53-67.
Read now
Read now
Thorsten Zenz & Stephan Stilgenbauer. (2009) Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survival. Leukemia & Lymphoma 50:10, pages 1559-1561.
Read now
Read now
Articles from other publishers (17)
Masahiko Takahashi, Kazuyoshi Hosomichi, Hirofumi Nakaoka, Haruhito Sakata, Naoya Uesato, Kentaro Murakami, Masayuki Kano, Takeshi Toyozumi, Yasunori Matsumoto, Tetsuro Isozaki, Nobufumi Sekino, Ryota Otsuka, Itsuro Inoue & Hisahiro Matsubara. (2022) Biased expression of mutant alleles in cancer-related genes in esophageal squamous cell carcinoma. Esophagus 19:2, pages 294-302.
Crossref
Crossref
Linlin Gao, Brent Harbaugh, Kevin Parr, Payal Patel, Shivani Golem, Da Zhang, Janet Woodroof & Wei Cui. (2022)
MYC Expression Is Associated With p53 Expression and
TP53
Aberration and Predicts Poor Overall Survival in Acute Lymphoblastic Leukemia/Lymphoma
. American Journal of Clinical Pathology 157:1, pages 119-129.
Crossref
Crossref
María José García-Iglesias, Jose Luis Cuevas-Higuera, Ana Bastida-Sáenz, María Gracia de Garnica-García, Laura Polledo, Paula Perero, Jorge González-Fernández, Beatriz Fernández-Martínez & Claudia Pérez-Martínez. (2020) Immunohistochemical detection of p53 and pp53 Ser392 in canine hemangiomas and hemangiosarcomas located in the skin. BMC Veterinary Research 16:1.
Crossref
Crossref
Satoko Oka, Kazuo Ono & Masaharu Nohgawa. (2020) Relationship between p53 expression and prognosis of myelodysplastic syndrome treated with azacitidine. Journal of Hematopathology 13:4, pages 213-219.
Crossref
Crossref
Rita Assi, Hatice D. Gur, Sanam Loghavi, Sergej N. Konoplev, Marina Konopleva, Naval Daver, Mehrnoosh Tashakori, Tapan Kadia, Mark Routbort, Alireza Salem, Rashmi Kanagal-Shamanna, Andres Quesada, Elias J. Jabbour, Steven M. Kornblau, L. Jeffrey Medeiros, Hagop Kantarjian & Joseph D. Khoury. (2018)
P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with
FLT3
internal tandem duplication and worse relapse-free survival
. American Journal of Hematology 93:11, pages 1376-1383.
Crossref
Crossref
Cordelia Sever, Charles L. Abbott, Monica E. de Baca, Joseph D. Khoury, Sherrie L. Perkins, Kaaren Kemp Reichard, Ann Taylor, Howard R. Terebelo, Carol Colasacco, R. Bryan Rumble & Nicole E. Thomas. (2016) Bone Marrow Synoptic Reporting for Hematologic Neoplasms: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center. Archives of Pathology & Laboratory Medicine 140:9, pages 932-949.
Crossref
Crossref
. 2014. Bone Marrow Diagnosis. Bone Marrow Diagnosis
108
160
.
Marian Jędrych, Ewelina Wawryk-Gawda, Barbara Jodłowska-Jędrych, Patrycja Chylińska-Wrzos & Ludwik Jasiński. (2013) Immunohistochemical evaluation of cell proliferation and apoptosis markers in ovarian surface epithelial cells of cladribine-treated rats. Protoplasma 250:5, pages 1025-1034.
Crossref
Crossref
ZHENSHU XU, JINYAN ZHANG, SHUNQUAN WU, ZHIHONG ZHENG, ZHIZHE CHEN & RONG ZHAN. (2013) Younger patients with chronic lymphocytic leukemia benefit from rituximab treatment: A single center study in China. Oncology Letters 5:4, pages 1266-1272.
Crossref
Crossref
Abraham M. Varghese, Andy C. Rawstron, Roger G. Owen & Peter Hillmen. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood
71
89
.
Kevin C. Gatter, Georges Delsol, Roger A. Warnke & Francesco Pezzella. 2011. The Diagnosis of Lymphoproliferative Diseases. The Diagnosis of Lymphoproliferative Diseases
75
80
.
Waleed AlduaijAndrei Ivanov, Jamie HoneychurchEleanor J. CheadleSandeep PotluriSean H. Lim, Kazuyuki Shimada, Claude H. T. Chan, Alison Tutt, Stephen A. Beers, Martin J. Glennie, Mark S. Cragg & Tim M. Illidge. (2011) Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 117:17, pages 4519-4529.
Crossref
Crossref
Waleed Alduaij & Tim M. Illidge. (2011) The future of anti-CD20 monoclonal antibodies: are we making progress?. Blood 117:11, pages 2993-3001.
Crossref
Crossref
Neil E. Kay, Jeanette E. Eckel-Passow, Esteban Braggio, Scott VanWier, Tait D. Shanafelt, Daniel L. Van Dyke, Diane F. Jelinek, Renee C. Tschumper, Thomas Kipps, John C. Byrd & Rafael Fonseca. (2010) Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genetics and Cytogenetics 203:2, pages 161-168.
Crossref
Crossref
Constantine S Tam & Michael J. Keating. 2010. Diagnostic Techniques in Hematological Malignancies. Diagnostic Techniques in Hematological Malignancies
171
190
.
M Hallek, K Fischer, G Fingerle-Rowson, AM Fink, R Busch, J Mayer, M Hensel, G Hopfinger, G Hess, U von Grünhagen, M Bergmann, J Catalano, PL Zinzani, F Caligaris-Cappio, JF Seymour, A Berrebi, U Jäger, B Cazin, M Trneny, A Westermann, CM Wendtner, BF Eichhorst, P Staib, A Bühler, D Winkler, T Zenz, S Böttcher, M Ritgen, M Mendila, M Kneba, H Döhner & S Stilgenbauer. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. The Lancet 376:9747, pages 1164-1174.
Crossref
Crossref
Paloma Martin, Ayoma D. Attygalle, John Swansbury, Toon Min, Alison Morilla, Sarah L. Hockley, Andrew Wotherspoon, Gareth J. Morgan, Daniel Catovsky, Claire E. Dearden & Estella Matutes. (2010) p53 protein overexpression in bone marrow biopsies from chronic lymphocytic leukaemia is associated with TP53 deletion and resistance to fludarabine. Journal of Hematopathology 3:2-3, pages 61-68.
Crossref
Crossref